COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control (FIMARO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02913794
Recruitment Status : Unknown
Verified September 2016 by Boryung Pharmaceutical Co., Ltd.
Recruitment status was:  Recruiting
First Posted : September 26, 2016
Last Update Posted : July 26, 2017
Information provided by (Responsible Party):
Boryung Pharmaceutical Co., Ltd

Brief Summary:
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Condition or disease
Cardiovascular Diseases Hyperlipidemias

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1056 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments
Actual Study Start Date : October 11, 2016
Estimated Primary Completion Date : March 30, 2018
Estimated Study Completion Date : March 30, 2018

Primary Outcome Measures :
  1. Co-relation between blood pressure and dyslipidemia [ Time Frame: 12 weeks ]
    Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
1,056 patients

Inclusion Criteria:

  • Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
  • Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
  • Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration

Exclusion Criteria:

  • Patients being hospitalized
  • Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
  • Patients who have more than 400mg/dl triglyceride(TG) at the registration time

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02913794

Layout table for location contacts
Contact: Myung-Sook Hong

Layout table for location information
Korea, Republic of
Severance Hospital Recruiting
Seoul, Korea, Republic of
Contact: Dong-Hoon Choie   
Sponsors and Collaborators
Boryung Pharmaceutical Co., Ltd
Layout table for investigator information
Study Director: Hyung-Jin Jung Boryung Pharmaceutical Co., Ltd
Layout table for additonal information
Responsible Party: Boryung Pharmaceutical Co., Ltd Identifier: NCT02913794    
Other Study ID Numbers: BR-FMS-OS-402
First Posted: September 26, 2016    Key Record Dates
Last Update Posted: July 26, 2017
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases